Pfizer's $22.45 Billion Trading Day Lands 17th in Market Activity
On April 29, 2025, Pfizer's trading volume reached $22.45 billion, marking a significant increase of 74.33% compared to the previous day, ranking 17th in the day's stock market activity. Pfizer's stock price rose by 3.21%, marking the fourth consecutive day of gains, with a total increase of 6.25% over the past four days.
Pfizer has announced that it will invest $1.5 billion in a new manufacturing facility in the United States. This investment is part of the company's strategy to expand its production capacity and meet the growing demand for its products. The new facility is expected to create over 1,000 jobs and will be operational by the end of 2027.
Pfizer has also received approval from the FDA for its new COVID-19 vaccine, which is designed to provide protection against the latest variants of the virus. The vaccine has shown promising results in clinical trials, with a high efficacy rate and a favorable safety profile. This approval is expected to boost Pfizer's revenue and market share in the vaccine market.
In addition, pfizer has announced that it will acquire a biotechnology company specializing in gene therapy. This acquisition is part of Pfizer's strategy to diversify its product portfolio and expand into new therapeutic areas. The acquisition is expected to close in the fourth quarter of 2025, subject to regulatory approval.
